Author Affiliations: Department of Dermatology, Stanford University School of Medicine, Redwood City, California (Drs Aasi, Tang, Wysong, Oro, and Chang and Mr Liu); Division of Ophthalmic Plastic, Reconstructive, and Orbital Surgery, California Pacific Medical Center, Oakland (Dr Silkiss); and Children's Hospital Oakland, Research Institute Oakland, California (Dr Epstein).
While keratoacanthomas (KAs) and squamous cell carcinomas (SCCs) have been reported in response to a number of systemic drugs such as vemurafenib, sorafenib, or voriconazole,1-3 their association with Smoothened inhibitors has not been previously noted. Herein, we report 2 cases of new KAs developing within 2 months of starting vismodegib therapy in individuals with no history of KAs or SCCs.
Aasi S, Silkiss R, Tang JY, et al. New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases. JAMA Dermatol. 2013;149(2):242–243. doi:10.1001/jamadermatol.2013.1798
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: